Moberg Pharma AB Share Price

Equities

MOB

SE0020353928

Pharmaceuticals

Market Closed - Nasdaq Stockholm 09:30:00 19/07/2024 pm IST 5-day change 1st Jan Change
38.46 SEK +3.78% Intraday chart for Moberg Pharma AB +2.07% +153.03%

Financials

Sales 2024 * 6M 562K 47.07M Sales 2025 * 42M 3.94M 329M Capitalization 1.8B 168M 14.09B
Net income 2024 * -29M -2.72M -228M Net income 2025 * -22M -2.06M -173M EV / Sales 2024 * 260 x
Net cash position 2024 * 239M 22.36M 1.87B Net cash position 2025 * 199M 18.65M 1.56B EV / Sales 2025 * 38 x
P/E ratio 2024 *
-5.49 x
P/E ratio 2025 *
-7.69 x
Employees 9
Yield 2024 *
-
Yield 2025 *
-
Free-Float 68.86%
More Fundamentals * Estimated data
Dynamic Chart
1 day+3.78%
1 week+2.07%
Current month+32.35%
1 month+30.99%
3 months+25.20%
6 months+153.03%
Current year+153.03%
More quotes
1 week
36.08
Extreme 36.08
39.32
1 month
26.60
Extreme 26.6
39.32
Current year
13.30
Extreme 13.3
40.90
1 year
6.15
Extreme 6.15
40.90
3 years
6.15
Extreme 6.15
75.50
5 years
6.15
Extreme 6.15
806.00
10 years
6.15
Extreme 6.15
861.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 01/06/01
Director of Finance/CFO 46 01/15/01
Chief Tech/Sci/R&D Officer 60 01/23/01
Members of the board TitleAgeSince
Director/Board Member 66 16/22/16
Director/Board Member 62 16/23/16
Director/Board Member 52 01/21/01
More insiders
Date Price Change Volume
19/24/19 38.46 +3.78% 423,081
18/24/18 37.06 +1.37% 197,169
17/24/17 36.56 -0.33% 272,418
16/24/16 36.68 -1.66% 216,826
15/24/15 37.3 -1.01% 484,262

Delayed Quote Nasdaq Stockholm, July 19, 2024 at 09:30 pm IST

More quotes
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Calendar
More about the company

Annual profits - Rate of surprise